MedTrace Logo

Tool for Evaluating the Effectiveness of the DENVER Protocol

NCT06253793 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2024-05-14

No results posted yet for this study

Summary

Early remediation of the communicative and social difficulties of children with autism spectrum disorders (ASD) is central. However, from the age of 6-8 months, children with ASD show a lack of attention to social stimuli such as faces: such early avoidance behavior could be at the root of later communicative difficulties (language, attention). The Denver program aims to stimulate social communication and attention to faces in children with ASD aged between 18 and 60 months. Although the Denver protocol is currently recommended by the French National Authority for Health (HAS), the Denver protocol has not yet been widely used or evaluated in France, mainly due to a lack of tools adapted to non-verbal populations. The goal of FaceCom is to help clinicians to evaluate the efficiency of the Denver Protocol.

Conditions

Sponsors & Collaborators

  • University Grenoble Alps

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Mathilde FORT, PhD · University Grenoble Alps

  • Isabelle Palacios, MD · Alps-Isere Hospital Center

Eligibility

Min Age
18 Months
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2027-05-31
Completion
2028-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06253793 on ClinicalTrials.gov